<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV) is a human herpesvirus that establishes a lifelong <z:e sem="disease" ids="C0872054" disease_type="Disease or Syndrome" abbrv="">latent infection</z:e> of B cells </plain></SENT>
<SENT sid="1" pm="."><plain>Within the immune system, <z:mpath ids='MPATH_3'>apoptosis</z:mpath> is a central mechanism in <z:mpath ids='MPATH_458'>normal</z:mpath> lymphocyte homeostasis both during early lymphocyte development and in response to antigenic stimuli </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we found that latent membrane protein 2A (LMP2A) inhibited B-cell receptor (BCR)-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="28088">Genistein</z:chebi>, a specific inhibitor of tyrosine-specific protein kinases, blocked BCR-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and EBV reactivation in the cells </plain></SENT>
<SENT sid="4" pm="."><plain>These findings indicate that LMP2A blocks BCR-induced cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and EBV reactivation through the inhibition of activation of tyrosine kinases by BCR cross-linking </plain></SENT>
</text></document>